Cargando…

Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation

OBJECTIVES: Costs may play a role in deciding how and when to start highly active antiretroviral therapy (HAART) in a naïve patient. The aim of the present study was to assess the cost- effectiveness of treatment with HAART in a large clinical cohort of naïve adults to determine the potential role o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maggiolo, Franco, Colombo, Giorgio L, Di Matteo, Sergio, Bruno, Giacomo M, Astuti, Noemi, Di Filippo, Elisa, Masini, Giulia, Bernardini, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337626/ https://www.ncbi.nlm.nih.gov/pubmed/25733942 http://dx.doi.org/10.2147/PROM.S63586

Ejemplares similares

Reduced adherence to antiretroviral therapy is associated with residual low-level viremia
por: Maggiolo, Franco, et al.
Publicado: (2017)

Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen
por: Colombo, Giorgio L, et al.
Publicado: (2013)

Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health status
por: Maggiolo, Franco, et al.
Publicado: (2014)

When to Start Antiretroviral Therapy
por: Jain, Vivek, et al.
Publicado: (2010)

When to start antiretroviral therapy: as soon as possible
por: Franco, Ricardo A, et al.
Publicado: (2013)

Single-Tablet Regimens in HIV Therapy
por: Astuti, Noemi, et al.
Publicado: (2014)

When Should Children with HIV Infection Be Started on Antiretroviral Therapy?
por: Welch, Steven B, et al.
Publicado: (2008)

Long-term effect of a four-drugs induction regimen for patients with high baseline viral load
por: Maggiolo, Franco, et al.
Publicado: (2014)

Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines
por: Colombo, Giorgio L, et al.
Publicado: (2013)

Cryptococcal meningoencephalitis in HIV/AIDS: when to start antiretroviral therapy?
por: Franco-Paredes, Carlos, et al.
Publicado: (2017)

The cost of antiretroviral therapy in Haiti
por: Koenig, Serena P, et al.
Publicado: (2008)

Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
por: Colombo, Giorgio L, et al.
Publicado: (2013)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

Cost-Effectiveness of Antiretroviral Therapy for Prevention
por: Kahn, James G, et al.
Publicado: (2011)

When should antiretroviral therapy be started in HIV-positive persons?
por: Sabin, Caroline A
Publicado: (2010)

Predicting virological decay in patients starting combination antiretroviral therapy
Publicado: (2016)

Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life
por: Maswabi, Kenneth, et al.
Publicado: (2020)

Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda
por: Sempa, Joseph, et al.
Publicado: (2012)

Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe’s national antiretroviral therapy programme between 2012 and 2015
por: Makurumidze, Richard, et al.
Publicado: (2020)

Immediate start of antiretroviral, why not?
por: Matsuda, Elaine Monteiro, et al.
Publicado: (2018)

Is Antiretroviral Therapy Cost-Effective in South Africa?
por: Braithwaite, R. Scott, et al.
Publicado: (2006)

Rapidly starting antiretroviral therapy to improve outcomes among disadvantaged groups
por: Ford, Nathan, et al.
Publicado: (2021)

Response to second line antiretroviral therapy in India
por: Singh, Anup, et al.
Publicado: (2012)

Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
por: Maggi, Paolo, et al.
Publicado: (2022)

Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa
por: Onoya, Dorina, et al.
Publicado: (2017)

First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda
por: Castelnuovo, Barbara, et al.
Publicado: (2016)

Association of First-Line and Second-Line Antiretroviral Therapy Adherence
por: Ramadhani, Habib O., et al.
Publicado: (2014)

Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?
por: Kumarasamy, N., et al.
Publicado: (2011)

Appropriate Time to Start Antiretroviral Therapy in HIV-infected Patients with Penicilliosis marneffei
por: Utkham, Thongchai, et al.
Publicado: (2017)

Use of Third Line Antiretroviral Therapy in Latin America
por: Cesar, Carina, et al.
Publicado: (2014)

Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy
por: Perrone, Valentina, et al.
Publicado: (2023)

Patient preferences for characteristics of antiretroviral therapies: results from five European countries
por: Gazzard, Brian, et al.
Publicado: (2014)

Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy
por: Al Hajjar, Sami Hussain, et al.
Publicado: (2012)

Hypertriglyceridemia in Antiretroviral Therapy
por: Imarhiagbe, Frank Aiwansoba, et al.
Publicado: (2005)

Initiation of antiretroviral therapy
por: Pandhi, Deepika, et al.
Publicado: (2014)

Individualization of antiretroviral therapy
por: Pavlos, Rebecca, et al.
Publicado: (2011)

Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received
por: Motta, Davide, et al.
Publicado: (2012)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy
por: Mahy, Mary, et al.
Publicado: (2010)

Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy
por: Jose, Sophie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p27udclf0qk13gtiup1tjnpsgl